|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.58 CNY | +0.03% |
|
+0.51% | -11.68% |
| 07-01 | Tranche Update on Tibet Rhodiola Pharmaceutical Holding Co.'s Equity Buyback Plan announced on December 18, 2025. | CI |
| 05-08 | Tibet Rhodiola Pharmaceutical Holding's board elects chairman | RE |
Company Valuation: Tibet Rhodiola Pharmaceutical Holding Co.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 16,681 | 12,982 | 8,906 | 12,099 | 11,906 | 13,715 |
| Change | - | -22.18% | -31.4% | 35.86% | -1.59% | 15.19% |
| Enterprise Value (EV) 1 | 15,908 | 12,218 | 7,462 | 10,226 | 9,555 | 11,106 |
| Change | - | -23.19% | -38.93% | 37.05% | -6.56% | 16.23% |
| P/E | 39.8x | 62.3x | 24.1x | 15.1x | 11.3x | 14.6x |
| PBR | 6.48x | 4.94x | 2.96x | 3.62x | 3.04x | 3.61x |
| PEG | - | -1.2x | 0.3x | 0x | 0.4x | -1.4x |
| Capitalization / Revenue | 12.1x | 6.07x | 3.49x | 3.86x | 4.24x | 4.6x |
| EV / Revenue | 11.6x | 5.71x | 2.92x | 3.26x | 3.4x | 3.72x |
| EV / EBITDA | 32.8x | 18.7x | 9.85x | 9.25x | 9.87x | 11.1x |
| EV / EBIT | 39.1x | 21.3x | 10.8x | 9.85x | 10.7x | 12x |
| EV / FCF | 207x | -208x | 16.3x | 17.5x | 19.8x | 15.9x |
| FCF Yield | 0.48% | -0.48% | 6.14% | 5.73% | 5.06% | 6.28% |
| Dividend per Share 2 | 0.3923 | 0.26 | 0.5738 | 1.492 | 1.957 | 1.757 |
| Rate of return | 0.76% | 0.65% | 2.08% | 3.97% | 5.3% | 4.13% |
| EPS 2 | 1.3 | 0.6462 | 1.146 | 2.485 | 3.26 | 2.91 |
| Distribution rate | 30.2% | 40.2% | 50.1% | 60% | 60% | 60.4% |
| Net sales 1 | 1,373 | 2,139 | 2,555 | 3,134 | 2,807 | 2,982 |
| EBITDA 1 | 485 | 654.2 | 757.5 | 1,105 | 967.6 | 1,002 |
| EBIT 1 | 407.3 | 572.7 | 688.3 | 1,039 | 893.4 | 924.7 |
| Net income 1 | 418.1 | 208.9 | 369.8 | 800.9 | 1,051 | 937.9 |
| Net Debt 1 | -773.1 | -763.6 | -1,444 | -1,873 | -2,351 | -2,609 |
| Reference price 2 | 51.75 | 40.28 | 27.63 | 37.54 | 36.94 | 42.55 |
| Nbr of stocks (in thousands) | 322,319 | 322,319 | 322,319 | 322,319 | 322,319 | 322,319 |
| Announcement Date | 3/11/21 | 3/11/22 | 3/10/23 | 3/26/24 | 3/14/25 | 3/12/26 |
1CNY in Million2CNY
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 1.76B | ||
| 36.12x | 13.12x | 26.72x | 0.55% | 1,102B | ||
| 28.52x | 6.55x | 17.81x | 2% | 643B | ||
| 31.52x | 7.52x | 15.4x | 2.69% | 450B | ||
| 18.05x | 4.49x | 11.1x | 2.95% | 336B | ||
| 21.91x | 5.62x | 13.6x | 2.8% | 288B | ||
| 14.45x | 5.37x | 11.03x | 3.47% | 222B | ||
| 24.08x | 6.37x | 11.22x | 2.74% | 199B | ||
| -48.34x | 5.87x | 32.62x | 2.38% | 169B | ||
| 11.78x | 3.02x | 7.46x | 7.27% | 137B | ||
| Average | 15.34x | 6.44x | 16.33x | 2.98% | 354.69B | |
| Weighted average by Cap. | 24.29x | 8.19x | 18.81x | 2.15% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 600211 Stock
- Valuation Tibet Rhodiola Pharmaceutical Holding Co.
Select your edition
All financial news and data tailored to specific country editions
















